Skip to main content
Log in

Premature ovarian insufficiency: from pathogenesis to clinical management

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Premature ovarian insufficiency (POI) represents a condition characterized by the absence of normal ovarian function due to an incipient (by 3–10 years) ovarian aging. In most of the women affected there are no signs or symptoms that precede the interruption of menstruation and the onset of POI and the majority of women have a normal history of menarche, regular menstrual cycles and normal fertility. The possible genetic role in the development of POI has been largely demonstrated and many genes have been involved; on the other hand, ovary is not protected immunologically and the detection of autoantibodies directed against various ovarian targets strongly support the hypothesis of an autoimmune etiology. In approximately 5–10 % of women with a diagnosis of POI with a normal karyotype, a spontaneous pregnancy could occur even if the recovery of ovarian function is temporary and poorly predictable. Embryo donation and adoption are other alternatives that should be considered. POI and subsequent loss of reproductive capacity is a devastating condition and a difficult diagnosis for women to accept so it requires an individualized and a multidisciplinary approach. Hormonal replacement therapy (HRT) should be commenced as soon as possible to prevent and to contrast the onset of the symptoms related to hypoestrogenism and to improve the quality of life for these women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cox L, Liu JH (2014) Primary ovarian insufficiency: an update. Int J Womens Health 20(6):235–243

    Google Scholar 

  2. ESHRE Capri Workshop Group (2005) Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 11:513–525

    Article  Google Scholar 

  3. Broekmans FJ, Soules MR, Fauser BC (2009) Ovarian aging: mechanisms and clinical consequences. Endocr Rev 30:465–493

    Article  CAS  PubMed  Google Scholar 

  4. Van Asselt KM, Kok HS, Pearson PL et al (2004) Heritability of menopausal age in mothers and daughters. Fertil Steril 82:1348–1351

    Article  PubMed  Google Scholar 

  5. Janse F, Knauff EA, Niermeijer MF et al (2010) Dutch Premature Ovarian Failure Consortium. Similar phenotype characteristics comparing familial and sporadic premature ovarian failure. Menopause 17:758–765

    PubMed  Google Scholar 

  6. Cordts BC, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP (2011) Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet 283:635–643

    Article  PubMed  Google Scholar 

  7. Karnis MF (2012) Fertility, pregnancy, and medical management of Turner syndrome in the reproductive years. Fertil Steril 98:787–791

    Article  PubMed  Google Scholar 

  8. Bidet M (2011) Resumption of Ovarian Function and Pregnancies in 358 Patients with Premature Ovarian Failure. J Clin Endocrinol Metab 96:3864–3872

    Article  CAS  PubMed  Google Scholar 

  9. Sullivan AK, Marcus M, Epstein MP et al (2005) Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 20:402–412

    Article  CAS  PubMed  Google Scholar 

  10. Otsuka F, McTavish KJ, Shimasaki S (2011) Integral role of GDF-9 and BMP-15 in ovarian function. Mol Reprod Dev 78:9–21

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Yoon SH, Choi YM, Hong MA et al (2010) Estrogen receptor alpha gene polymorphisms in patients with idiopathic premature ovarian failure. Hum Reprod 25:283–287

    Article  CAS  PubMed  Google Scholar 

  12. Rafique S, Sterling E, Lawrence N (2012) A new approach to primary ovarian insufficiency. Obstet Gynecol Clin N Am 39:567–586

    Article  Google Scholar 

  13. Hoek A, Schoemaker J, Drexhage HA (1997) Premature ovarian failure and ovarian autoimmunity. Endocr Rev 18:107–134

    CAS  PubMed  Google Scholar 

  14. La Marca A, Marzotti S, Brozzetti A et al (2009) Italian Addison Network. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J Clin Endocrinol Metab 94:3816–3823

    Article  PubMed  Google Scholar 

  15. Bedoschi G, Turan V, Oktay K (2013) Utility of GnRH-agonists for fertility preservation in women with operable breast cancer: is it protective? Curr Breast Cancer Rep 5:302–308

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Trikudanathan S, Pedley A, Massaro JM et al (2013) Association of female reproductive factors with body composition: the Framingham Heart Study. J Clin Endocrinol Metab 98:236–244

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Kinney A, Kline J, Kelly A, Reuss ML, Levin B (2007) Smoking, alcohol and caffeine in relation to ovarian age during the reproductive years. Hum Reprod 22:1175–1185

    Article  CAS  PubMed  Google Scholar 

  18. Iorio R, Castellucci A, Ventriglia G et al (2014) Ovarian toxicity: from environmental exposure to chemotherapy. Curr Pharm Des 20:5388–5397

    Article  CAS  PubMed  Google Scholar 

  19. Knauff EAH, Eijkemans MJC, Lambalk CB et al (2009) Anti-Műllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 94:786–792

    Article  CAS  PubMed  Google Scholar 

  20. Van der Steeg JW, Steures P, Eijkemans MJ et al (2007) Predictive value and clinical impact of basal follicle-stimulating hormone in subfertile, ovulatory women. J Clin Endocrinol Metab 92:2163–2168

    Article  PubMed  Google Scholar 

  21. Van Disseldorp J, Lambalk CB, Kwee J et al (2010) Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 25:221–227

    Article  PubMed  Google Scholar 

  22. Luisi S, Ciani V, Podfigurna-Stopa A et al (2012) Serum anti-Müllerian hormone, inhibin B, and total inhibin levels in women with hypothalamic amenorrhea and anorexia nervosa. Gynecol Endocrinol 28:34–38

    Article  CAS  PubMed  Google Scholar 

  23. Andersen CY, Byskov AG (2006) Estradiol and regulation of anti-Müllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles’ fluid. J Clin Endocrinol Metab 91:4064–4069

    Article  CAS  PubMed  Google Scholar 

  24. Silberstein T, MacLaughlin DT, Shai I et al (2006) Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod 21:159–163

    Article  CAS  PubMed  Google Scholar 

  25. Kalantaridou SN, Naka KK, Bechlioulis A, Makrigiannakis A, Michalis L, Chrousos GP (2006) Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol Metab 17:101–109

    Article  CAS  PubMed  Google Scholar 

  26. Rocca WA, Bower JH, Maraganore DM et al (2008) Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70:200–209

    Article  CAS  PubMed  Google Scholar 

  27. Primary ovarian insufficiency in adolescent and young women. Committee Opinion. No 605. ACOG. Obstet and Gynecol 2014, 123: 193-7

  28. Rebar RW (2009) Premature ovarian failure. Obstet Gynecol 113:1355–1363

    Article  PubMed  Google Scholar 

  29. Parker WH, Broder MS, Chang E et al (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ Health Study. Obstet Gynecol 113:1027–1037

    Article  PubMed Central  PubMed  Google Scholar 

  30. Nelson LM (2009) Clinical practice. Primary ovarian insufficiency. N Engl J Med 360:606–614

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Scarabin PY, Oger E, Plu-Bureau G (2003) Estrogen and ThromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428–432

    Article  CAS  PubMed  Google Scholar 

  32. Bachmann G, Bancroft J, Braunstein G et al (2002) Princeton. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77:660–665

    Article  PubMed  Google Scholar 

  33. Martyn-St James M, Carroll S (2008) Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. Bone 43:521–531

    Article  PubMed  Google Scholar 

  34. De Caro JJ, Dominguez C, Sherman SL (2008) Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile x-associated primary ovarian insufficiency. Ann N Y Acad Sci. 1135:99–111

    Article  PubMed  Google Scholar 

  35. Lucas K, Hensel D (2014) Fertility preservation options for women treated for cancer. Nurs Womens Health 18:138–147

    Article  PubMed  Google Scholar 

  36. Krieg SA, Henne MB, Westphal LM (2008) Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies. Fertil Steril 90:65–70

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Luisi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luisi, S., Orlandini, C., Regini, C. et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J Endocrinol Invest 38, 597–603 (2015). https://doi.org/10.1007/s40618-014-0231-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-014-0231-1

Keywords

Navigation